

SEER Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2002-2011

Prepared for PDF format by Patients Against Lymphoma

www.lymphomation.org

Lymphoma Subtype	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	35.5	291,708	-0.1	5.8	13,801	0.9	23.5	124,330	-0.5*	158.8	153,577	0
1 Hodgkin Lymphoma	2.8	23,039	-0.4	1.2	2,871	1.1	3.2	16,085	-0.7	4.2	4,083	-0.1
2 Non-Hodgkin lymphoma	31.7	259,916	0	4.6	10,841	0.8	19.7	105,264	-0.3*	148.8	143,811	0.2
2(a) Non-Hodgkin lymphoma, B-cell	29.1	238,256	0.3	3.4	8,059	2.8*	17.8	94,938	-0.2	139.9	135,259	0.4
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.3	10,680	3.7*	2.8	6,477	3.4*	0.6	3,175	3.5*	1.1	1,028	5.6*
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	26.4	216,653	-0.1	0.6	1,483	-0.2	16.4	88,107	-0.4*	131.5	127,063	0.1
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	6.5	53,393	-1.1*	0	25	-	3.3	17,926	-1.3*	36.6	35,442	-0.9*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	5.8	46,977	-1.4*	0	21	-	2.8	15,546	-1.7*	32.4	31,410	-1.3*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0	200	-2.3	-	-	-	0	51	-	0.2	145	-2.5
2(a) 2.1.3. Mantle-cell lymphoma	0.8	6,216	1.7*	0	0	-	0.4	2,329	0.9	4	3,887	2.1*
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.6	5,089	-1.7*	-	-	-	0.3	1,547	-2.2*	3.7	3,539	-1.5*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.3	2,268	0.7	-	-	-	0.1	706	-0.6	1.6	1,561	1.2
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.3	2,821	-3.5*	-	-	-	0.2	841	-3.5*	2	1,978	-3.5*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	6.9	56,521	0.2	0.3	634	-1.5	4.6	24,273	-0.5	32.7	31,614	0.6*
2(a) 2.3.1. DLBCL, NOS(c)	6.9	55,999	0.1	0.3	612	-2	4.5	23,860	-0.7*	32.6	31,527	0.6*
2(a) 2.3.2. Intravascular large B-cell lymphoma	0	67	-	0	0	-	0	25	-	0	42	-
2(a) 2.3.3. Primary effusion lymphoma	0	92	-	0	0	-	0	71	-	0	21	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0	363	10.9*	0	22	-	0.1	317	11.3*	0	24	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.4	3,345	0.9	0.3	666	-0.5	0.4	1,940	2.7	0.8	739	-2
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.9	15,680	1.7*	0	78	-	1.2	6,620	0.8*	9.3	8,982	2.2*
2(a) 2.5.1. Splenic MZL	0.2	1,317	0.1	0	0	-	0.1	523	-1.4	0.8	794	0.9
2(a) 2.5.2. Extranodal MZL, MALT(c) type	1.1	9,392	1.4*	0	51	-	0.8	4,225	0.6	5.3	5,116	1.9*
2(a) 2.5.3. Nodal MZL	0.6	4,971	2.7*	0	27	-	0.3	1,872	1.9*	3.2	3,072	3
2(a) 2.6. Follicular lymphoma	3.7	30,549	-0.8	0	67	-	3	15,697	-1.6*	15.3	14,785	-0.2
2(a) 2.7. Hairy-cell leukemia	0.3	2,456	-1.2	-	-	-	0.3	1,557	-0.9	0.9	898	-1.7
2(a) 2.8. Plasma cell neoplasms	6.1	49,576	0.7*	-	-	-	3.4	18,530	0.9*	32.2	31,037	0.6*
2(a) 2.8.1. Plasmacytoma	0.4	3,169	2.7*	-	-	-	0.3	1,564	2.4*	1.7	1,598	2.8*
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS(c)	1.3	10,923	5.1*	0	99	-	0.7	3,656	3.2*	7.4	7,168	5.9*
2(b) Non-Hodgkin lymphoma, T-cell	2.1	17,302	0.3	0.8	1,776	0.8	1.7	8,954	0.2	6.8	6,572	0.2
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.2	1,292	-4.2	0.3	628	-3.2	0.1	559	-6.1	0.1	105	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.9	15,876	0.8	0.5	1,143	3.0*	1.6	8,327	0.8	6.6	6,406	0.4
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.5	3,953	1	0	91	-	0.5	2,370	1.1	1.5	1,492	0.6
2(b) 2.1.1. Mycosis fungoides	0.5	3,836	0.8	0	91	-	0.4	2,329	1	1.5	1,416	0.3
2(b) 2.1.2. Sezary syndrome	0	117	-	0	0	-	0	41	-	0.1	76	-
2(b) 2.2. Peripheral T-cell lymphoma	1.1	9,446	-0.2	0.2	412	-3.5	0.9	4,787	-0.3	4.4	4,247	0.1
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS(c)	0.4	3,358	0.1	0	74	-	0.3	1,599	-0.7	1.8	1,685	0.9
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	1,117	4.9*	-	-	-	0.1	448	3.9	0.7	666	5.3*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0	116	-	0	18	-	0	70	-	0	28	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	1,982	-3.5*	0.1	244	-4.2	0.2	1,125	-1.9	0.6	613	-5.7*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0	73	-	-	-	-	0	52	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0	102	-	0	0	-	0	52	-	0.1	50	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS(c)	0.2	1,840	-1	0	30	-	0.2	978	-0.3	0.9	832	-2
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	858	0.4	0	31	-	0.1	463	0.4	0.4	364	0.7
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.2	1,357	6.6*	0.3	613	7.3*	0.1	535	8.9*	0.2	209	0
2(b) 2.4. NK(c)/T-cell lymphoma, nasal-type/ aggressive NK(c)-cell leukemia	0.1	644	3.5*	0	26	-	0.1	432	2.3	0.2	186	6.5*
2(b) 2.5. T-cell large granular lymphocytic leukemia	0	201	-	-	-	-	0	83	-	0.1	117	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0	275	3.2	0	0	-	0	120	-	0.2	155	4.0*
2(b) 3. Non-Hodgkin lymphoma, NOS(c), T-cell	0	134	-	-	-	-	0	68	-	0.1	61	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.5	4,358	-12.2*	0.4	1,006	-13.8*	0.3	1,372	-11.6*	2	1,980	-11.3*
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage	0.2	1,842	-12.8*	0.4	986	-13.8*	0.1	485	-11.9*	0.4	371	-10.1*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0	100	-	-	-	-	0	31	-	0.1	67	-
2(c) 3. Non-Hodgkin lymphoma, NOS(c), unknown lineage	0.3	2,416	-	0	18	-	0.2	856	-	1.6	1,542	-
2(*) 1. Total precursor lymphoma/leukemia(d)	1.7	13,814	0.5	3.4	8,091	0.6	0.8	4,219	0.2	1.6	1,504	1.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0	157	5.8	-	-	-	0	85	-	0.1	70	-
4 Lymphoid neoplasm, NOS® *	1.1	8,596	-4.3*	0	87	-	0.6	2,896	-5.1*	5.7	5,613	-4.1*

The APC is the Annual Percent Change over the time interval.

SEER(b) Incidence Rates and Annual Percent Change by Age at Diagnosis

(c) NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

(*) The APC is significantly different from zero (p<.05).

(-) Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.